Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes

Diabetes and Vascular Disease Research

Volumn 12, Issue 3, 2015, Pages 154-163

  Koska, Juraj ^a   Sands, Michelle ^a   Burciu, Camelia ^a   Reaven, Peter ^a  

^a Phoenix Veterans Affairs Health Care System   (United States)

Author keywords

Cardiovascular; dipeptidyl peptidase 4; glucagon like peptide 1; incretins; type 2 diabetes

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; SAXAGLIPTIN; ADAMANTANE; BIOLOGICAL MARKER; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL; INCRETIN; PIPERIDINE DERIVATIVE; URACIL;

ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD VESSEL INJURY; BODY WEIGHT; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DIABETIC PATIENT; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME INHIBITION; GLYCEMIC CONTROL; HEART FUNCTION; HEART PROTECTION; HUMAN; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; METABOLISM; PROTECTION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ADAMANTANE; ANIMALS; BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; INCRETINS; PIPERIDINES; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; URACIL;

EID: 84926433000     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164114562411     Document Type: Review

References (80)

1. Centers for Disease Control and Prevention. National diabetes fact sheet, 2011: national estimates and general information on diabetes and prediabetes in the United States. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf (accessed 14 August 2014).
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 ; 321: 405-412
3. Riddle MC, Karl DM. Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials. Diabetes Care. 2012 ; 35: 2100-2107
4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006 ; 368: 1696-1705
5. Fadini GP, Albiero M, Menegazzo L, et al. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients. Diabetes Obes Metab. 2012 ; 14: 518-522
6. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011 ; 60: 1917-1925
7. De Falco E, Porcelli D, Torella AR, et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood. 2004 ; 104: 3472-3482
8. Gomez N, Touihri K, Matheeussen V, et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail. 2012 ; 14: 14-21
9. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care. 2007 ; 30: 1335-1343
10. Pesquero JB, Jubilut GN, Lindsey CJ, et al. Bradykinin metabolism pathway in the rat pulmonary circulation. J Hypertens. 1992 ; 10: 1471-1478
11. Brown NJ, Gainer JV, Stein CM, et al. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension. 1999 ; 33: 1431-1435
12. Oliver JJ, Webb DJ, Newby DE. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol. 2005 ; 25: 2470-2479
13. Hancock JC, Lindsay GW. Enhanced ganglionic responses to substance P in spontaneously hypertensive rats. Peptides. 2000 ; 21: 535-541
14. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care. 2010 ; 33: 442-449
15. Navab M, Reddy ST, Van Lenten BJ, et al. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011 ; 8: 222-232
16. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007 ; 116: 1832-1844
17. Balletshofer BM, Rittig K, Enderle MD, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation. 2000 ; 101: 1780-1784
18. Goldberg IJ. Clinical review 124: diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001 ; 86: 965-971
19. Xiao C, Hsieh J, Adeli K, et al. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am J Physiol Endocrinol Metab. 2011 ; 301: E429 - E446
20. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011 ; 121: 2111-2117
21. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002 ; 106: 2067-2072
22. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004 ; 109: III27 - III32
23. Halcox JP, Donald AE, Ellins E, et al. Endothelial function predicts progression of carotid intima-media thickness. Circulation. 2009 ; 119: 1005-1012
24. Yeboah J, Crouse JR, Hsu FC, et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation. 2007 ; 115: 2390-2397
25. Du XL, Edelstein D, Dimmeler S, et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest. 2001 ; 108: 1341-1348
26. Morigi M, Angioletti S, Imberti B, et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest. 1998 ; 101: 1905-1915
27. Benjamin EJ, Larson MG, Keyes MJ, et al. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation. 2004 ; 109: 613-619
28. Creager MA, Luscher TF, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation. 2003 ; 108: 1527-1532
29. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004 ; 141: 421-431
30. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010 ; 362: 800-811
31. Cobble M. Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2012 ; 4: 8
32. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011 ; 154: 602-613
33. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012 ; 33: 187-215
34. Schwartz EA, Koska J, Mullin MP, et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis. 2010 ; 212: 217-222
35. Matikainen N, Manttari S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006 ; 49: 2049-2057
36. DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008 ; 24: 2943-2952
37. Eliasson B, Moller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 2012 ; 55: 915-925
38. Monami M, Lamanna C, Desideri CM, et al. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012 ; 29: 14-25
39. Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care. 2011 ; 34: S276 - S278
40. Monami M, Ahren B, Dicembrini I, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013 ; 15: 112-120
41. Mason RP, Jacob RF, Kubant R, et al. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol. 2012 ; 60: 467-473
42. Mason RP, Jacob RF, Kubant R, et al. Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb. 2011 ; 18: 774-783
43. Van Poppel PC, Netea MG, Smits P, et al. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011 ; 34: 2072-2077
44. Matsubara J, Sugiyama S, Akiyama E, et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013 ; 77: 1337-1344
45. Ayaori M, Iwakami N, Uto-Kondo H, et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc. 2013 ; 2: e003277
46. Ta NN, Schuyler CA, Li Y, et al. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2011 ; 58: 157-166
47. Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011 ; 124: 2338-2349
48. Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1α. Diabetes Care. 2010 ; 33: 1607-1609
49. Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 2013 ; 227: 349-354
50. Sauve M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010 ; 59: 1063-1073
51. Chaykovska L, Von Websky K, Rahnenfuhrer J, et al. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One. 2011 ; 6: e27861
52. Yin M, Sillje HH, Meissner M, et al. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol. 2011 ; 10: 85
53. Read PA, Khan FZ, Heck PM, et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010 ; 3: 195-201
54. Witteles RM, Keu KV, Quon A, et al. Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy. J Card Fail. 2012 ; 18: 804-809
55. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 ; 369: 1317-1326
56. Cardiovascular and Renal Microvascular outcome study with linagliptin in patients with type 2 diabetes mellitus at high vascular risk. ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/NCT01897532?term=NCT01897532&rank=1 (accessed 7 August 2014).
57. Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013 ; 166: 983-989.e7
58. Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res. 2013 ; 10: 289-301
59. Zaruba MM, Theiss HD, Vallaster M, et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell. 2009 ; 4: 313-323
60. Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005 ; 45: 1449-1457
61. Tepper OM, Galiano RD, Capla JM, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002 ; 106: 2781-2786
62. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004 ; 287: E1209 - E1215
63. Basu A, Charkoudian N, Schrage W, et al. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 2007 ; 293: E1289 - E1295
64. Katout M, Zhu H, Rutsky J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2014 ; 27: 130-139
65. Devin JK, Pretorius M, Nian H, et al. Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. Hypertension. 2014 ; 63: 951-957
66. Williams-Herman D, Round E, Swern AS, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord. 2008 ; 8: 14
67. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010 ; 122: 16-27
68. Johansen OE, Neubacher D, Von Eynatten M, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012 ; 11: 3
69. Schweizer A, Dejager S, Foley JE, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab. 2010 ; 12: 485-494
70. White WB, Pratley R, Fleck P, et al. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab. 2013 ; 15: 668-673
71. Hirshberg B, Raz I. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care. 2011 ; 34: S101 - S106
72. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 ; 369: 1327-1335
73. Butler PC, Elashoff M, Elashoff R, et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?. Diabetes Care. 2013 ; 36: 2118-2125
74. Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care. 2013 ; 36: 2126-2132
75. White WB. Cardiovascular outcomes with alogliptin in patients with type 2 diabetes mellitus and recent acute coronary syndromes. Presented at European Association for the Study of Diabetes ; Barcelona ;..
76. Hirshberg B, Katz A. Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care. 2013 ; 36: S253 - S258
77. Reaven PD, Moritz TE, Schwenke DC, et al. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes. 2009 ; 58: 2642-2648
78. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 ; 358: 2545-2559
79. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014 ; 24: 689-697
80. Wu S, Hopper I, Skiba M, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014 ; 32: 147-158